Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics

MLA

Oliver Koch, et al. “Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics.” SSRN Electronic Journal, Jan. 2021. EBSCOhost, https://doi.org/10.2139/ssrn.3958859.

APA

Oliver Koch, Andrew Duncan, Jean Antonelli, Timothy S. Walsh, Annya Bruce, Kay Russell, Colin Ferrett, Colin Church, James S. O. McCullagh, Jürgen Schwarze, Cecilia Boz, Giulia Rinaldi, Sinéad Plant, Gareth Hardisty, Anne Moore, Ahsan R. Akram, Kourosh Honarmand Ebrahimi, Sarah McNamara, Feng Li, … Sunny Jabball. (2021). Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3958859

Chicago

Oliver Koch, Andrew Duncan, Jean Antonelli, Timothy S. Walsh, Annya Bruce, Kay Russell, Colin Ferrett, et al. 2021. “Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics.” SSRN Electronic Journal, January. doi:10.2139/ssrn.3958859.